Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Lang Daniel	2. Date of Event Requiring Statement (MM/DD/YYYY) 11/22/2021	3. Issuer Name and Ticker or Trading Symbol Athenex, Inc. [ATNX]
(Last)        (First)        (Middle) C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                          _____ 10% Owner ___X___ Officer (give title below)        _____ Other (specify below) Pres Cell Therapy, VP Corp Dev /
(Street) BUFFALO, NY 14203       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	73413 (1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	8/27/2030	Common Stock	40000	$10.25	D
Stock Option (Right to Buy)	(3)	9/16/2031	Common Stock	50000	$2.77	D
Restricted Stock Units	(4)	(4)	Common Stock	50000	(5)	D

Explanation of Responses:
(1)	Includes 30,000 shares subject to a restricted stock award vesting in four equal installments beginning on August 26, 2020.
(2)	This option vests in four equal annual installments beginning on August 27, 2021.
(3)	This option vests in four equal annual installments beginning on September 16, 2022.
(4)	The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
(5)	Each restricted stock unit represents a contingent right to receive one share of stock.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Lang Daniel C/O ATHENEX, INC., 1001 MAIN STREET SUITE 600 BUFFALO, NY 14203			Pres Cell Therapy, VP Corp Dev

Signatures
/s/Steven Adams, Attorney-in-Fact		12/1/2021
**Signature of Reporting Person		Date